{"entity":{"id":"nct05296564","kind":"trial","name":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","aka":[],"tldr":"A phase 1/2 trial of cyclophosphamide and aldesleukin (high-dose il-2) in triple-negative breast cancer, run by Hadassah Medical Organization, now recruiting.","summary":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers is a phase 1/2, interventional study registered as NCT05296564 by Hadassah Medical Organization, with a registry enrolment figure of 3 participants, started 2022-04-01 and due to reach its primary completion in 2027-12-30. Interventions recorded: CYCLOPHOSPHAMIDE and FLUDARABIN; Cyclophosphamide; HBI 0201-ESO TCRT; Aldesleukin. Conditions listed: Sarcoma, Synovial; Sarcoma,Soft Tissue; Melanoma Stage IV; Triple Negative Breast Cancer; Metastatic Cancer; Non Small Cell Lung Cancer; Bladder Urothelial Carcinoma; Neuroblastoma, Metastatic; Ovary Cancer. Sites: Israel. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05296564","url":"https://clinicaltrials.gov/study/NCT05296564"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["cyclophosphamide","aldesleukin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05296564","phase":"1/2","setting":"A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","sponsor":"Hadassah Medical Organization","enrolled":3,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05296564/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}